Læknablaðið - 15.11.1997, Qupperneq 30

742
LÆKNABLAÐIÐ 1997; 83
erosclerotic disease in a prospective Finnish population
based study. Atherosclerosis 1994; 106: 9-19.
67. Boushey CJ, Beresford SA, Omenn GS, Motulsky
AG. A quantitative assessment of plasma homocys-
teine as a risk factor for vascular disease. Probable
benefíts of increasing folic acid intakes. JAMA 1995;
274: 1049-57.
72. Arnesen E, Refsum H, Böná KH, Ueland PM, Förde
OH, Nordrehaug JE. Serum total homocysteine and
coronary heart disease. Int J Epidemiol 1995; 24:
704-9.
73. Nygárd O, Nordrehaug JE, Refsum H, Ueland PM,
Farstad M, Vollset SE. Plasma homocysteine levels
and mortality in patients with coronary artery disease.
New Engl J Med 1997: 337: 230-6.
74. Graham IM, Daly LE, Refsum HM, Robinson K,
Brattström LE, Ueland PM, et al. Plasma homocys-
teine as a risk factor for vascular disease: the European
Concerted Action Project. JAMA 1997; 277: 1775—81.
75. Bostom AG, Jacques PF, Nadeau MR, Williams RR,
Ellison RC, Selhub J. Post-methionine load hyperho-
mocysteinemia in persons with normal fasting total
plasma homocysteine: initial results from the NHLBI
family heart study. Atherosclerosis 1995; 116: 147-51.
81. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub
J, Horsford J, et al. Methylenetetrahydrofolate reduc-
tase polymorphism, plasma folate, homocysteine, and
risk of myocardial infarcion in US physicians. Circula-
tion 1996; 94: 2410-6.
87. Verhoef P, KokFJ, Kluitmans LAJ, Blom HJ, Refsum
H, Ueland PM, et al. Combination of mutated methy-
lenetetrahydrofolate reductase and low folate status is
associated with high plasma total homocysteine (the-
sis). Wagenringen Agricultural University, 1996; ISBN
90-5485-500-2: 31-43.
89. Brattström L. A common mutation in the gene of
methylenetetrahydrofolate reductase: evidence against
mild hyperhomocysteinemia being a causal risk factor
for cardiovascular disease. Circulation. In press 1997.
91. Faure-Delanef L, Chassé JF, Quéré I, Guerassimenko
O, Lesaulnier M, Kamoun P, et al. Human longevity
and cardiovascular risk: implication of an MTHFR
thermolabile variant. J Inher Metab Dis 1996; 19/Suppl.
1: 24.
95. Robinson K, Gupta A, Dennis V, Arheart K, Chaud-
hary D. Green R, et al. Hyperhomocysteinemia con-
fers an independent increased risk of atherosclerosis in
end-stage renal disease and is closely linked to plasma
folate and pyridoxine concentrations. Circulation 1996;
94: 2743-8.
96. Nygárd O, Vollset SE, Refsum H, Stensvold I, Tverdal
Á, Nordrehaug JE, et al. Total plasma homocysteine
and cardiovascular risk profile: the Hordaland homo-
cysteine study. JAMA 1995; 274: 1526-33.
100. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR,
Haak HL, Wijermans PW, et al. Is hyperhomocystei-
nemia a risk factor for recurrent venous thrombosis?
Lancet 1995: 345: 882-5.
101. den Heijer M, Koster T, Blom HJ, Bos GMJ. Briet E,
Reitsma PH, et al. Hyperhomocysteinemia as a risk
factor for deep-vein thrombosis. N Engl J Med 1996;
334: 759-62.
106. Wilcken DEL, Dudman NPB. Mechanism of thrombo-
genesis and accelerated atherogenesis in homocystei-
nemia. Haemostasis 1989; 19/Suppl. 1: 14-23.
108. Harker LA, Ross R, Slichter SJ, Scott CR. Homocys-
teine-induced arteriosclerosis. The role of endothelial
cell injury and platelet response in its genesis. J Clin
Invest 1976; 58: 731-41.
109. Jakubowski H. Metabolism of homocysteine thiolac-
tone in human cell cultures. J Biol Chem 1997; 272:
1935-42.
110. Wood JL, Graham A. Structural requirements for ox-
idation of low-density lipoproteins by thiols. FEBS Let-
ters 1995; 366: 75-80.
113. Tawakol A, Omland T, Gerhard M, Wu JT, Creager
MA. Hyperhomocyst(e)inemia is associated with im-
paired endothelium-dependent vasodilation in hu-
mans. Circulation 1997; 95: 1119-21.
130. Stampfer MJ, Malinow MR. Can lowering homocys-
teine levels reduce cardiovascular risk (editorial)? New
Engl J Med 1995; 322: 328-9.
133. Food and Drug Administration. Food standards:
amendment of standards of identity for enriched grain
products to require addition of folic acid. Final rule.
Fed Regist 1996; 61: 8781-807.
134. Campbell NRC. How safe are folic acid suplements?
Arch Intern Med 1996; 156: 1638-44.